<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01463098</url>
  </required_header>
  <id_info>
    <org_study_id>E2006-A001-001</org_study_id>
    <nct_id>NCT01463098</nct_id>
  </id_info>
  <brief_title>A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006</brief_title>
  <official_title>A 2-Part, Randomized, Double-blind, Placebo- and Active- Controlled, Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Subjects and Otherwise Healthy Subjects With Primary Insomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      Part A: The purpose of this study is to evaluate the safety and tolerability of single oral
      doses of E2006 administered in the morning to healthy male and female subjects.

      Part B: The purpose of this study is to evaluate selected pharmacodynamic (PD) parameters
      (e.g., polysomnographically defined sleep measures) with regard to dose response in subjects
      with primary insomnia following single oral dosing of E2006 in the evening approximately 30
      minutes prior to the sleep period, compared with 10 mg zolpidem and placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability by monitoring the number of subjects with adverse events</measure>
    <time_frame>4 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: plasma concentrations of E2006</measure>
    <time_frame>up to 72 hours postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>E2006 1.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>E2006 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>E2006 5.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>E2006 10.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>E2006 25.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>E2006 50.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>E2006 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>E2006 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>zolpidem 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>zolpidem matched placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>zolpidem - matched placebo (Part B Only)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E2006 - matched placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Part A and Part B)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2006 1.0 mg</intervention_name>
    <description>1.0 mg, or placebo</description>
    <arm_group_label>E2006 1.0 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2006 2.5 mg</intervention_name>
    <description>2.5 mg or placebo</description>
    <arm_group_label>E2006 2.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2006 5.0 mg</intervention_name>
    <description>5.0 mg or placebo</description>
    <arm_group_label>E2006 5.0 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2006 10.0 mg</intervention_name>
    <description>10.0 mg or placebo</description>
    <arm_group_label>E2006 10.0 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2006 25.0 mg</intervention_name>
    <description>25.0 mg or placebo</description>
    <arm_group_label>E2006 25.0 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2006 50.0 mg</intervention_name>
    <description>50.0 mg or placebo</description>
    <arm_group_label>E2006 50.0 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2006 100 mg</intervention_name>
    <description>100mg or placebo</description>
    <arm_group_label>E2006 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2006 200 mg</intervention_name>
    <description>200 mg or placebo</description>
    <arm_group_label>E2006 200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zolpidem 10 mg</intervention_name>
    <description>10 mg</description>
    <arm_group_label>zolpidem 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zolpidem - matched placebo</intervention_name>
    <description>Part B only</description>
    <arm_group_label>zolpidem matched placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2006 - matched placebo</intervention_name>
    <description>(Part A and Part B)</description>
    <arm_group_label>E2006 - matched placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

        Healthy Subjects:

          -  With habitual time in bed &gt; 7 hours, with lights out 2200 to 2400 and lights on 0600
             to 0800

          -  Who report typical sleep latency of &lt;/= 30 minutes

          -  With typical total sleep time (TST) &gt;/= 420 minutes

        Primary Insomnia Subjects:

          -  Otherwise healthy adult male and female subjects with a diagnosis of primary insomnia
             (as defined by the Diagnostic and Statistical Manual of Mental Disorders-IV-Text
             Revision [DSM-IV-TR]) present at the time of Screening for at least 3 months

          -  With a score of &gt; 15 on the Insomnia Severity Index (ISI) at Screening

          -  Who report taking &gt;/= 30 minutes to fall asleep on at least 3 nights per week for the
             past month

          -  Who report 6.5 hours sleep or less on at least 3 nights per week for the past month

          -  With mean latency to persistent sleep (LPS) on both baseline nights of &gt;/= 20 minutes
             with neither night &lt; 15 minutes

          -  With mean wake after sleep onset (WASO) &gt;/= 20 minutes on both baseline nights, with
             neither night &lt; 15 minutes or mean TST &gt; 420 minutes

        Key Exclusion Criteria:

          -  With a current history of sleep disorders (e.g., obstructive sleep apnea, restless leg
             syndrome [RLS], narcolepsy, or circadian rhythm disorder) other than primary insomnia
             (for Part B)

          -  Subjects with any clinically abnormal symptom or organ impairment found in medical
             history, symptoms/signs, vital signs, ECG finding, or laboratory test results which
             require medical treatment

          -  All females must be of non-childbearing potential

          -  With a known history of significant neurological or serious psychiatric illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mardik Donikyan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinilabs, Inc. 423 West 55th Street, 4th Floor New York, NY 10019</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinilabs, Inc.</name>
      <address>
        <city>New York,</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2011</study_first_submitted>
  <study_first_submitted_qc>October 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2011</study_first_posted>
  <last_update_submitted>May 20, 2013</last_update_submitted>
  <last_update_submitted_qc>May 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolpidem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

